Home › NDC Lookup › RxCUI directory › RxCUI 2381144

Fenfluramine 2.2 MG/ML Oral Solution [Fintepla] — RxCUI 2381144

RxNorm drug concept · Semantic branded drug
RxCUI 2381144 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2381144
Official nameFenfluramine 2.2 MG/ML Oral Solution [Fintepla]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asFintepla 2.2 MG/ML Oral Solution; fenfluramine 2.2 MG/ML (as fenfluramine HCl 2.5 MG/ML) Oral Solution [Fintepla]
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)17,553 prescriptions · 45 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Fenfluramine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Fintepla treats seizures from two rare epilepsy types, Dravet syndrome and Lennox-Gastaut syndrome. It's approved for people 2 years and older.
  • It's a liquid taken twice a day, with or without food. Use the oral syringe from the pharmacy, because a kitchen spoon isn't accurate. It can also go through a feeding tube. Throw...
  • Fenfluramine can cause heart valve disease and high blood pressure in the lung arteries. Echocardiograms are done before you start, every 6 months, and 3 to 6 months after your las...
  • Lower appetite, weight loss, sleepiness, diarrhea, constipation, vomiting and tiredness are common. Call your doctor for breathing trouble, swelling, mood changes, suicidal thought...
📖 Read our full Fenfluramine guide →

🕸️ Concept Web — How Fenfluramine 2.2 MG/ML Oral Solution [Fintepla] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Fenfluramine 2.2 MG/ML Oral Solution [Fintepla] RxCUI 2381144

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Fenfluramine 4328
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Fintepla 2381139
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Fenfluramine Oral Solution 2381137
    • Fenfluramine Oral Liquid Product 2381136
    • Fenfluramine Oral Product 1159036
    • Fenfluramine Oral Solution [Fintepla] 2381141
    • Fintepla Oral Liquid Product 2381142
    • Fintepla Oral Product 2381143
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Fenfluramine 2.2 MG/ML Oral Solution SCD · 2381138
  • Fenfluramine 2.2 MG/ML SCDC · 2381135
  • Fenfluramine Oral Solution SCDF · 2381137
  • Fenfluramine Oral Liquid Product SCDG · 2381136
  • Fenfluramine Oral Product SCDG · 1159036

Brand-Name Concepts

  • Fenfluramine 2.2 MG/ML [Fintepla] SBDC · 2381140
  • Fenfluramine Oral Solution [Fintepla] SBDF · 2381141
  • Fintepla Oral Liquid Product SBDG · 2381142
  • Fintepla Oral Product SBDG · 2381143
  • Fintepla BN · 2381139

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2381144 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
43376-0322-30 1 BOTTLE, PLASTIC in 1 CARTON (43376-322-30) / 30 mL in 1 B... Fintepla UCB, Inc. 2020-07-15
43376-0322-36 1 BOTTLE, PLASTIC in 1 CARTON (43376-322-36) / 360 mL in 1... Fintepla UCB, Inc. 2020-07-15
Observed labelers: UCB, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.